Aarti Drugs Ltd. consolidated net profit grew 33% in the fourth quarter of the last financial year.
The pharmaceutical company posted a profit of Rs 63 crore in the quarter ended March, according to an exchange filing on Tuesday.
Aarti Drugs Q4 FY25 Highlights (Consolidated, YoY)
Revenue up 9% to Rs 676 crore versus Rs 620 crore.
Ebitda up 8% to Rs 93.2 crore versus Rs 86.1 crore.
Margin narrows to 13.8% versus 13.9%.
Net profit up 33% to Rs 63 crore versus Rs 47.4 crore.
Shares of Aarti Drugs closed 1.45% lower at Rs 349.9 apiece on the National Stock Exchange before the results were announced, compared to a 0.33% decline in the benchmark Nifty.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.